The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2364-2370

  Kim, H R ^a   Lim, S M ^a,b   Kim, H J ^c   Hwang, S K ^c   Park, J K ^d   Shin, E ^d   Bae, M K ^b   Ou, S H I ^e   Wang, J ^f   Jewell, S S ^g   Kang, D R ^b   Soo, R A ^h   Haack, H ⁱ   Kim, J H ^a,b   Shim, H S ^b   Cho, B C ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c JE UK Institute for Cancer Research   (South Korea)

^d CFC Pathology Laboratory   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Norvatis   (United States)

^g Abbott Molecular Inc   (United States)

^h NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁱ CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

Lung adenocarcinoma; Never smoker; Outcome; ROS1

Indexed keywords

CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PEMETREXED; PLATINUM DERIVATIVE;

ADULT; AGED; ALK GENE; ARTICLE; CANCER PROGNOSIS; CD74 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FREQUENCY; GENE FUSION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; KOREA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SMOKING; TREATMENT OUTCOME;

LUNG ADENOCARCINOMA; NEVER SMOKER; OUTCOME; ROS1;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENE REARRANGEMENT; GLUTAMATES; GUANINE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKING; TREATMENT OUTCOME;

EID: 84883343307     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt220     Document Type: Article

References (18)

1. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13(10): 1011-1019.
2. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118(3): 729-739.
3. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30(8): 863-870.
4. Wang R, Hu H, Pan Y, et al. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30 (35): 4352-4359.
5. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131(6): 1190-1203.
6. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18(3): 378-381.
7. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18(16): 4449-4457.
8. Ou SH, Tan J, Yen Y, et al. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 2012; 12(4): 447-456.
9. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012; 18(17): 4570-4579.
10. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; 74(1): 132-138.
11. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011; 6(11): e28204.
12. Cai W, Li X, Su C, et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol 2013; 24: 1822-1827.
13. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011; 6(4): 774-780.
14. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150(6): 1121-1134.
15. Suehara Y, Arcila M, Wang L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012; 18(24): 6599-6608.
16. Yoshida A, Kohno T, Tsuta K, et al. ROS1-Rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013; 37(4): 554-562.
17. Martinez P, Hernandez-Losa J, Montero MA, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 2013; 8(1): e52261.
18. Conde E, Angulo B, Izquierdo E, et al. The ALK translocation in advanced nonsmall- cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology 2013; 62(4): 609-616.